Cisplatin: mode of cytotoxic action and molecular basis of resistance
The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ATM kinase seems to be activated primarily in response to the induction of double-strand breaks whereas ATR is critical for cellular checkpoint responses to stalled replication forks and to many types of DNA damage, such as those induced by UV light and cisplatin (16,17).”
In the citing paper
“Clinical use of cisplatin is complicated by the dose-limiting side effects as well as rapid development of drug resistance [5].”
Citations
Cites
1 retracted
BRCA1 required for transcription-coupled repair of oxidative DNA damage
Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998) · Science · doi:10.1126/science.281.5379.1009 · Cited by 496
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 2×
“Intracellular factors that may inhibit such an activation of p53 include overexpression of the negative feedback regulator Mdm2 and downregulation of the moderator of Mdm2, p14ARF (Fritsche et al., 1993; Shieh et al., 1997; Lakin and Jackson, 1999; Meek, 1999; Deng et al., 2002).”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“…resistance-associated (MRP) gene family, composed of at least seven members (MRP1–7), has been a major target of investigations, primarily as several of these ABC membrane proteins have been found in tumor cells and associated with cellular efflux of a variety of drugs (Borst et al., 2000).”
Background
Research works printed but not linked: 5
- Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH. (1997). Blood, 90, 935–943. · doi:10.1182/blood.v90.3.935.935_935_943 · Paper page
- Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R . (1990). Carboplatin: Current Perspectives and Future Directions. Bunn P, Canetta R, Ozols R and Rozencweig M (eds). WB Saunders Company: Philadelphia, PA, pp. 133–140.
- He G and Siddik ZH . (2001). Proc. Am. Assoc. Cancer Res., 42, 901.
- Holford J, Rogers P and Kelland LR . (1998). Int. J. Cancer, 77, 94–100. · doi:10.1002/(sici)1097-0215(19980703)77:1<94::aid-ijc15>3.0.co;2-9
- Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF . (2001). Clin. Cancer Res., 7, 2984–2997.
Cited by
Items 501–600 of 1,004
Heffeter, P., Pongratz, M., Steiner, E., Chiba, P., Jakupec, M. A., Elbling, L., Marian, B., Körner, W., Sevelda, F., Micksche, M., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073395 · Cited by 76
Anticancer activity, DNA-binding and DNA-denaturing aptitude of palladium(II) dithiocarbamates
Amir, M. K., Khan, S. Z., Hayat, F., Hassan, A., Butler, I. S., & Rehman, Z. (2016) · Inorganica Chimica Acta · doi:10.1016/j.ica.2016.06.036 · Cited by 76
Role of Akt signaling in resistance to DNA-targeted therapy
Avan, A., Narayan, R. S., Giovannetti, E., & Peters, G. J. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i5.352 · Cited by 80
Tomar, A., Vasisth, S., Khan, S. I., Malik, S., Nag, T. C., Arya, D. S., & Bhatia, J. (2017) · Phytomedicine · doi:10.1016/j.phymed.2017.05.007 · Cited by 76
c-Jun Regulates the Stability and Activity of the p53 Homologue, p73
Toh, W. H., Siddique, M. M., Boominathan, L., Lin, K. W., & Sabapathy, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407672200 · Cited by 77
Rikiishi, H., Shinohara, F., Sato, T., Sato, Y., Suzuki, M., & Echigo, S. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.5.1181 · Cited by 87
Karaca, Ö., Meier, S. M., Casini, A., & Kühn, F. E. (2017) · Chemical Communications · doi:10.1039/c7cc03074f · Cited by 79
Negrette-Guzmán, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172513 · Cited by 74
Links between cancer metabolism and cisplatin resistance
Cocetta, V., Ragazzi, E., & Montopoli, M. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.01.005 · Cited by 80
Subcellular localization of biomolecules and drug distribution by high-definition ion beam imaging
Rovira-Clavé, X., Jiang, S., Bai, Y., Zhu, B., Barlow, G., Bhate, S., Coskun, A. F., Han, G., Ho, C.-M. K., Hitzman, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24822-1 · Cited by 73
Transplatin Is Cytotoxic When Photoactivated: Enhanced Formation of DNA Cross-Links
Heringová, P., Woods, J. A., Mackay, F. S., Kašpárková, J., Sadler, P. J., & Brabec, V. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0606692 · Cited by 74
Redox State-Dependent Interaction of HMGB1 and Cisplatin-Modified DNA
Park, S., & Lippard, S. J. (2011) · Biochemistry · doi:10.1021/bi2000214 · Cited by 74
Yu, W., Jin, C., Lou, X., Han, X., Li, L., He, Y., Zhang, H., Ma, K., Zhu, J., Cheng, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029450 · Cited by 74
Liu, R.-Y., Dong, Z., Liu, J., Yin, J., Zhou, L., Wu, X., Yang, Y., Mo, W., Huang, W., Khoo, S. K., et al. (2011) · Oncogene · doi:10.1038/onc.2011.189 · Cited by 78
Prachařová, J., Zerzánková, L., Štěpánková, J., Nováková, O., Farrer, N. J., Sadler, P. J., Brabec, V., & Kašpárková, J. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300057y · Cited by 75
Shah, M., Ullah, N., Choi, M. H., Kim, M. O., & Yoon, S. C. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.11.014 · Cited by 76
Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy
Li, J., Hao, D., Wang, L., Wang, H., Wang, Y., Zhao, Z., Li, P., Deng, C., & Di, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-04406-0 · Cited by 81
Park, J. Y., Choi, P., Kim, T., Ko, H., Kim, H.-K., Kang, K. S., & Ham, J. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5b00782 · Cited by 75
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer
Michels, J., Vitale, I., Senovilla, L., Enot, D. P., Garcia, P., Lissa, D., Olaussen, K. A., Brenner, C., Soria, J.-C., Castedo, M., et al. (2013) · Cell Cycle · doi:10.4161/cc.24034 · Cited by 73
Pharmacogenomics of platinum-based chemotherapy in NSCLC
Hildebrandt, M. A. T., Gu, J. H., & Wu, X. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902973711 · Cited by 76
Keter, F. K., Kanyanda, S., Lyantagaye, S., Darkwa, J., Rees, D. J. G., & Meyer, M. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0721-y · Cited by 89
Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer
Pan, Y., Yang, H., & Claret, F. X. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.27823 · Cited by 74
“In addition, increased DDR has been reported to be one of the mechanisms of chemotherapy or radiotherapy resistance.(3,4) Therefore, studies of DNA damage and repair can elucidate the fundamental mechanisms triggering tumorigenesis and provide novel strategies for tumor therapy.”
BackgroundNucleoside–Lipid-Based Nanoparticles for Cisplatin Delivery
Khiati, S., Luvino, D., Oumzil, K., Chauffert, B., Camplo, M., & Barthélémy, P. (2011) · ACS Nano · doi:10.1021/nn202291k · Cited by 74
Jarman, P. J., Noakes, F. F., Fairbanks, S. D., Smitten, K. L., Griffiths, I. K., Saeed, H. K., Thomas, J. A., & Smythe, C. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b09999 · Cited by 73
New anti-cancer strategies: Epigenetic therapies and biomarkers
Balch, C. (2005) · Frontiers in bioscience · doi:10.2741/1668 · Cited by 77
Sun, J., Pan, L.-M., Chen, L., & Wang, Y. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1361071 · Cited by 71
“Cisplatin primarily acts by causing DNA damage.(4)”
RetractedKim, H. S., Hwang, J. T., Yun, H., Chi, S., Lee, S., Kang, I., Yoon, K., Choe, W.-J., Kim, S. S., & Ha, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704432200 · Cited by 83
RetractedFanzani, A., Zanola, A., Rovetta, F., Rossi, S., & Aleo, M. F. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.11.003 · Cited by 79
Pu, X., Hildebrandt, M. A. T., Lu, C., Lin, J. M., Stewart, D. J., Ye, Y., Gu, J. H., Spitz, M. R., & Wu, X. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.04.008 · Cited by 75
Júnior, Á. D. D. C., Mota, L. G., Nunan, E. A., Wainstein, A. J. A., Wainstein, A. P. D. L., Leal, A. S., Cardoso, V. N., & Oliveira, M. C. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.10.011 · Cited by 72
Song, Y., Suntharalingam, K., Yeung, J. S., Royzen, M., & Lippard, S. J. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400281a · Cited by 72
Combination of chrysin and cisplatin promotes the apoptosis of Hep G2 cells by up-regulating p53
Li, X., Huang, J., Wang, J., Xiong, X.-K., Yang, X., & Zou, F. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.03.003 · Cited by 78
Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy
LaPensee, E. W., & Ben‐Jonathan, N. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0253 · Cited by 74
Ding, L., Yuan, C., Feng, W., Wang, G., Zhang, J., Bellail, A. C., Zhang, Z., Olson, J. J., & Hao, C. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.605412 · Cited by 76
Cisplatin encapsulation within a ferritin nanocage: a high-resolution crystallographic study
Pontillo, N., Pane, F., Messori, L., Amoresano, A., & Merlino, A. (2016) · Chemical Communications · doi:10.1039/c5cc10365g · Cited by 76
The relationship between platinum drug resistance and epithelial–mesenchymal transition
Brozović, A. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1912-7 · Cited by 77
Saifi, M. A., Sangomla, S., Khurana, A., & Godugu, C. (2018) · Biological Trace Element Research · doi:10.1007/s12011-018-1457-0 · Cited by 74
Emerging role of long non-coding RNAs in cisplatin resistance
Hu, Y., Zhu, Q.-N., Deng, J., Li, Z., Wang, G., & Zhu, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s158104 · Cited by 71
“The platinum atom of cisplatin interacts with nucleophilic N(7)-sites of purine in DNA to form inter- and intra-strand DNA crosslinks,(8,14) which results in DNA damage, cell cycle arrest, and activation of multiple signal transduction pathways, leading to cell apoptosis.(8,15) Moreover, cisplatininduced production of…”
Ghanbarian, M., Afgar, A., Yadegarazari, R., Najafi, R., & Teimoori‐Toolabi, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.112 · Cited by 71
Curcumin effect on cancer cells' multidrug resistance: An update
Keyvani‐Ghamsari, S., Khorsandi, K., & Gul, A. (2020) · Phytotherapy Research · doi:10.1002/ptr.6703 · Cited by 77
“in progress of the drug resistance (Razaghi, Heimann, Schaeffer, & Gibson, 2018; Siddik, 2003).”
BackgroundNanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance
Xie, P., Wang, Y., Wei, D., Zhang, L., Zhang, B., Xiao, H., Song, H., & Mao, X. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb00753j · Cited by 76
Hou, Y.-J., Dong, L., Tan, Y., Yang, G.-Z., Pan, Y., Li, Z., Tang, L., Wang, M., Wang, Q., & Wang, H. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.97 · Cited by 71
Leonhardt, K., Gebhardt, R., Mössner, J., Lutsenko, S., & Hüster, D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805145200 · Cited by 76
Yde, C. W., & Issinger, O. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.6.1397 · Cited by 82
Curtin, C. M., Nolan, J., Conlon, R., Deneweth, L., Gallagher, C., Tan, Y. J., Cavanagh, B., Asraf, A. Z., Harvey, H. M., Miller-Delaney, S. F. C., et al. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.02.004 · Cited by 77
“Cisplatin and other platin-containing drugs are routinely used in neuroblastoma treatment where it forms cross-links with DNA and blocks cell division leading to apoptotic cell death [64,65].”
BackgroundRecent Advances on the Development of Pharmacotherapeutic Agents on the Basis of Human Serum Albumin
Liu, F., Mu, J., & Xing, B. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150302115411 · Cited by 73
“For instance, metal-based platinum drugs such as cisplatin, carboplatin and oxaliplatin, have been widely used in clinics to treat a variety of solid tumors, which have been proposed to effectively suppress tumor progression by their interactions with DNA in tumor cells [32].”
BackgroundPathophysiological mechanisms of cardiotoxicity in chemotherapeutic agents
Chaulin, A. M., Abashina, O. E., & Duplyakov, D. V. (2020) · Russian Open Medical Journal · doi:10.15275/rusomj.2020.0305 · Cited by 77
Zhou, X., Fu, L., Wang, P., Yang, L., Zhu, X., & Li, C. G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111445 · Cited by 70
Huang, D., Chowdhury, S., Wang, H., Savage, S. R., Ivey, R. G., Kennedy, J. J., Whiteaker, J. R., Lin, C., Hou, X., Oberg, A. L., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100471 · Cited by 83
Bertrand, B., Spreckelmeyer, S., Bodio, E., Cocco, F., Picquet, M., Richard, P., Gendre, P. L., Orvig, C., Cinellu, M. A., & Casini, A. (2015) · Dalton Transactions · doi:10.1039/c5dt01023c · Cited by 81
Pithi Chanvorachote, B., Pongrakhananon, V., Wannachaiyasit, S., Luanpitpong, S., Rojanasakul, Y., & Nimmannit, U. (2009) · Cancer Investigation · doi:10.1080/07357900802653472 · Cited by 79
Hour, T., Lai, Y., Kuan, C.-I., Chou, C., Wang, J., Tu, H.-Y., Hu, H., Lin, C., Wu, W., Pu, Y., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.007 · Cited by 71
Simonin, K., Brotin, É., Dufort, S., Dutoit, S., Goux, D., N’Diaye, M., Denoyelle, C., Gauduchon, P., & Poulain, L. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0493 · Cited by 76
Genetic susceptibility in cervical cancer: From bench to bedside
Bahrami, A., Hasanzadeh, M., Shahidsales, S., Farazestanian, M., Hassanian, S. M., Ahmadi, M. M., Maftouh, M., Gharib, M., Yousefi, Z., Kadkhodayan, S., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26019 · Cited by 80
“Genetic alterations may modify the cellular phenotype and lead to variability in terms of response and toxicity of cisplatin therapy (Siddik, 2003).”
BackgroundGanji, N., Rambabu, A., Vamsikrishna, N., Daravath, S., & Shivaraj, S. (2018) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2018.06.100 · Cited by 70
Nadin, S. B., Vargas-Roig, L. M., Drago, G., IBARRA, J., & Ciocca, D. R. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.07.025 · Cited by 70
Min, J., Veldhoven, P. P. V., Zhang, L., Hanigan, M. H., Alexander, H., & Alexander, S. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0197 · Cited by 70
Altaf, M., Monim-ul-Mehboob, M., Kawde, A.-N. M., Corona, G., Larcher, R., Ogasawara, M. A., Casagrande, N., Celegato, M., Borghese, C., Siddik, Z. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13448 · Cited by 70
“Cisplatin resistance is a critical factor that limits its clinical utility [1, 41].”
Self-citationA Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt IV Complexes under Physiological Conditions
Kastner, A., Poetsch, I., Mayr, J., Burda, J. V., Roller, A., Heffeter, P., Keppler, B. K., & Kowol, C. R. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201900682 · Cited by 76
Sutton, E. C., & DeRose, V. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100633 · Cited by 74
“1A), exerted their cytotoxic effects by triggering the DNA damage response (DDR) (12, 13).”
BackgroundSodium alginate-functionalized nanodiamonds as sustained chemotherapeutic drug-release vectors
Cui, Z., Zhang, Y., Zhang, J., Kong, H., Tang, X., Pan, L., Xia, K., Aldalbahi, A. K., Li, A., Tai, R., et al. (2015) · Carbon · doi:10.1016/j.carbon.2015.07.066 · Cited by 71
Wang, W., Sun, Y., Huang, X., He, M. Y., Chen, Y., Shi, G., Li, H., Yi, J., & Wang, J. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.006 · Cited by 75
Understanding trans platinum complexes as potential antitumor drugs beyond targeting DNA
Quiroga, A. G. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.002 · Cited by 69
Lee, M. K., Hande, M. P., & Sabapathy, K. (2005) · Journal of Cell Science · doi:10.1242/jcs.01673 · Cited by 69
Díaz, A., González, M. L., Pérez, R. J., David, A., Mukherjee, A., Baez, A. C., Clearfield, A., & Colón, J. L. (2013) · Nanoscale · doi:10.1039/c3nr02206d · Cited by 69
Kawasaki, Y., Okumura, H., Uchikado, Y., Kita, Y., Sasaki, K., Owaki, T., Ishigami, S., & Natsugoe, S. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3600-2 · Cited by 69
Jürgens, S., Kühn, F. E., & Casini, A. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170529125229 · Cited by 70
Yempala, T., Babu, T., Karmakar, S., Nemirovski, A., Ishan, M., Gandin, V., & Gibson, D. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201910014 · Cited by 70
Dyshlovoy, S. A., Hauschild, J., Amann, K., Tabakmakher, K. M., Venz, S., Walther, R., Guzii, A. G., Makarieva, T. N., Shubina, L. K., Fedorov, S. N., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4175 · Cited by 69
“As the mechanism of action of MonA strongly differs from standard agents used to treat these tumors [40], MonA might be a promising new substance capable of overcoming resistance against currently applied therapies [23, 33].”
Fuplatin: An Efficient and Low-Toxic Dual-Prodrug
Zhang, R., Song, X., Liu, R.-P., Ma, Z., & Xu, J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00128 · Cited by 74
Babu, T., Sarkar, A., Karmakar, S., Schmidt, C., & Gibson, D. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.0c00445 · Cited by 74
Animal models of chemotherapy-induced cognitive decline in preclinical drug development
John, J., Kinra, M., Mudgal, J., Viswanatha, G. L., & Nandakumar, K. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05977-7 · Cited by 67
“…purine residue of DNA to form DNA adducts by intra-strand cross-linkage and activate different downstream signaling pathways (ATR [ataxia telangiectasia and Rad3-related], p53, p73, MAPK [mitogen-activated protein kinase]) thereby blocking cell division and culminating in apoptosis (Siddik 2003).”
BackgroundIn vivo dual-targeted chemotherapy of drug resistant cancer by rationally designed nanocarrier
Wang, Y., Zhao, R., Wang, S., Liu, Z., & Tang, R. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.09.030 · Cited by 70
Plasencia, C., Martinez‐Balibrea, E., Martínez‐Cardús, A., Quinn, D. I., Abad, A., & Neamati, N. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.1.225 · Cited by 81
Barakat, B. M., Wang, Q., Han, C., Milum, K., Yin, D., Zhao, Q., Wani, G., Arafa, E. A., El‐Mahdy, M. A., & Wani, A. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.25112 · Cited by 76
Stiborová, M., Eckschlager, T., Poljaková, J., Hraběta, J., Adam, V., Kizek, R., & Frei, E. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712802884286 · Cited by 76
Wang, J., Biju, M. P., Wang, M.-H., Haase, V. H., & Dong, Z. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121371 · Cited by 68
Aloe emodin decreases the ERK-dependent anticancer activity of cisplatin
Mijatović, S., Maksimović‐Ivanić, D., Radovic, J., Miljković, D. M., Kaluđerović, G. N., Sabo, T. J., & Trajković, V. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5041-3 · Cited by 68
Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR-203
He-yi, Y., Xie, X., Zhang, W., Zhu, H.-L., & Jiang, F. (2016) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-016-0044-y · Cited by 68
Shati, A. A. (2018) · Systems Biology in Reproductive Medicine · doi:10.1080/19396368.2018.1541114 · Cited by 69
“…Shati shati100@yahoo.com Department of Biology, College of Science, King Khalid University, Abha, Saudi Arabia © 2018 Informa UK Limited, trading as Taylor & Francis Group However, Cis treatment is coupled with cellular resistance and only 15–20% of patients respond to the treatment (Siddik 2003).”
BackgroundActive targeting liposome-PLGA composite for cisplatin delivery against cervical cancer
Dana, P., Bunthot, S., Suktham, K., Surassmo, S., Yata, T., Namdee, K., Yingmema, W., Yimsoo, T., Ruktanonchai, U. R., Sathornsumetee, S., et al. (2020) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2020.111270 · Cited by 68
Bello, B. D., Moretti, D., Gamberucci, A., & Maellaro, E. (2006) · Oncogene · doi:10.1038/sj.onc.1210079 · Cited by 68
Ni, J., Hou, X., Wang, X., Shi, Y., Xu, L., Zheng, X., Liu, N., Qiu, A., & Zhuang, S. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1589-y · Cited by 72
Caffeic acid, a dietary polyphenol, as a promising candidate for combination therapy
Maity, S., Kinra, M., Nampoothiri, M., Arora, D. S., Pai, K. S. R., & Mudgal, J. (2021) · Chemical Papers · doi:10.1007/s11696-021-01947-7 · Cited by 76
Yang, H., Wang, W., Zhang, Y., Zhao, J., Lin, E., Gao, J., & He, J. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.03.012 · Cited by 70
Zeng, L., Li, Y., Li, T., Cao, W., Yi, Y., Geng, W., Sun, Z., & Xu, H. (2014) · Chemistry - An Asian Journal · doi:10.1002/asia.201402256 · Cited by 69
Wang, S., Wei, Q., Dong, G., & Dong, Z. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.023 · Cited by 68
Gupta, G., Garci, A., Murray, B. S., Dyson, P. J., Fabre, G., Trouillas, P., Giannini, F., Furrer, J., Süß‐Fink, G., & Therrien, B. (2013) · Dalton Transactions · doi:10.1039/c3dt51991k · Cited by 67
STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Lavecchia, A., Giovanni, C. D., & Novellino, E. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795843218 · Cited by 73
Singh, A. P., Singh, R. K., Kim, K., Satyan, K. S., Nussbaum, R. D., Torres, M. S., Brard, L., & Vorsa, N. (2009) · Phytotherapy Research · doi:10.1002/ptr.2667 · Cited by 67
Stravopodis (2009) · International Journal of Oncology · doi:10.3892/ijo_00000353 · Cited by 79
Živković, M. D., Kljun, J., Tomic, T. I., Pavić, A., Veselinović, A. M., Manojlović, D., Nikodinović‐Runić, J., & Turel, I. (2017) · Inorganic Chemistry Frontiers · doi:10.1039/c7qi00299h · Cited by 67
Aminuddin, A., Ng, P. Y., Leong, C., & Chua, E. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-64664-3 · Cited by 72
Aurora kinase inhibition downregulates NF-κB and sensitises tumour cells to chemotherapeutic agents
Sun, C., Chan, F., Briassouli, P., & Linardopoulos, S. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.11.004 · Cited by 77
Dynamic targeting of the replication machinery to sites of DNA damage
Solomon, D. A., Cardoso, M. C., & Knudsen, E. S. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200312048 · Cited by 67
Zheng, S., Wang, X., Weng, Y., Jin, X., Ji, J.-L., Guo, L.-X., Hu, B., Liu, N., Cheng, Q., Zhang, J., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.08.003 · Cited by 75
“These DNA adducts can activate several signal transduction pathways, including Erk, p53, p73, and MAPK, which culminates in the activation of apoptosis.(40,41) As a result, it will induce G2 arrest.”
BackgroundChemotherapy-Induced Myopathy: The Dark Side of the Cachexia Sphere
Campelj, D. G., Goodman, C. A., & Rybalka, E. (2021) · Cancers · doi:10.3390/cancers13143615 · Cited by 77
“This complex can bind with DNA residues to develop CDDP-DNA adducts, which induce DNA crosslinking and cell cycle arrest [69].”
BackgroundCurtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatment
Pabla, N., & Dong, Z. (2012) · Oncotarget · doi:10.18632/oncotarget.439 · Cited by 82
Tirado, Ò. M., Mateo‐Lozano, S., & Notario, V. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1276 · Cited by 66
Brabec, V., Howson, S. E., Kaner, R. A., Lord, R. M., Malina, J., Phillips, R. M., Abdallah, Q., McGowan, P. C., Rodger, A., & Scott, P. (2013) · Chemical Science · doi:10.1039/c3sc51731d · Cited by 65
Metadata
- Authors
- Siddik, Z. H.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Siddik, Zahid H
- ORCID
- Siddik, Zahid H
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7265-7279
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2164277862
- Cited by
- 3,335
- References
- 154
- Citations by year
- 2026: 67 · 2025: 94 · 2024: 127 · 2023: 161 · 2022: 195 · 2021: 216 · 2020: 203 · 2019: 181 · 2018: 184 · 2017: 185 · 2016: 215 · 2015: 193 · 2014: 205 · 2013: 175 · 2012: 165
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca077332-03)
- National Cancer Institute (CA-77332, R01CA082361, CA 82361)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- cisplatin, cisplatin resistance, DNA adducts, DNA cross-linking, apoptosis, ATR signaling, p53, p73, MAPK signaling, DNA damage response, drug uptake, drug inactivation, DNA repair, HER2/neu, PI3K/Akt signaling, Bcl-2, caspase activation, signal transduction
- MeSH terms
- Cisplatin, DNA Damage, DNA Repair, Humans, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.